Kazia Therapeutics Files May 2025 6-K Report
Ticker: KZIA · Form: 6-K · Filed: May 28, 2025 · CIK: 1075880
| Field | Detail |
|---|---|
| Company | Kazia Therapeutics LTD (KZIA) |
| Form Type | 6-K |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, corporate-update, foreign-private-issuer
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed its May 6-K, standard corporate update.
AI Summary
Kazia Therapeutics Limited filed a Form 6-K on May 28, 2025, reporting its activities for the month of May 2025. The company, previously known as Novogen Ltd, is based in Sydney, NSW, Australia, and operates in the pharmaceutical preparations sector. This filing is made under the Securities Exchange Act of 1934.
Why It Matters
This filing provides an update on Kazia Therapeutics' regulatory activities and corporate information for the specified period, which is important for investors tracking the company's compliance and operational status.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer activities and does not contain new material financial or operational information that would significantly alter risk.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- Sydney NSW (location) — Company address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes public in its home country, files with a stock exchange, or distributes to its security holders.
When was Kazia Therapeutics Limited previously known by another name?
Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a date of name change on December 28, 1998.
What is Kazia Therapeutics Limited's primary business sector?
Kazia Therapeutics Limited is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where is Kazia Therapeutics Limited's principal executive office located?
The principal executive office of Kazia Therapeutics Limited is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics Limited file annual reports under Form 20-F or 40-F?
Kazia Therapeutics Limited indicates that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 28, 2025 regarding KAZIA THERAPEUTICS LTD (KZIA).